Key facts
- Vincere Biosciences’s last known valuation is $40.0M (Apr 2025).
- It has raised $16.3M; the latest was Grant ($5.0M) in Nov 2025.
- Notable investors include Alumni Ventures, Draper Associates, Johnson & Johnson Innovation - JLABS, 2Raze, Beiersdorf — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Vincere Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Vincere Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vincere Biosciences
Developer of a biotechnology research platform designed to offer therapeutics for neurodegenerative disease. The company's platform is a patented biology simulation technology that integrates large-scale human genomic and biochemical data to facilitate research, clinical studies, and the creation of drugs that can restore mitochondrial quality, enabling medical researchers to access the drugs capable of treating Parkinson's disease painlessly.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2018
- Employees
- 9
- Website
- vincerebio.com/
- Ownership
- Privately Held (backing)
Vincere Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vincere Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vincere Biosciences in its N-PORT filings yet. We sweep new filings monthly.